The tie up is expected to accelerate the development of ImaginAb’s pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.
ImaginAb CEO Christian Behrenbruch said with their expanding pharma client base worldwide, ImaginAb is leveraging multiple manufacturing technologies to increase the capacity for fast, reliable protein production.
Eurogentec CSO Philippe Cronet said their technology platform is well suited to a variety of recombinant proteins including the important class of antibody fragment proteins such as those under development by ImaginAb.